Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16331859 | 0.91 | FYN (0.48) | CYP1A2CLK4CYP2C9ATRCYP3A4 | |
| SCHEMBL16332954 | 0.91 | CYP1A2 (0.57) | CYP1A2CLK4CYP2C9ATRCYP3A4 | |
| SCHEMBL16332059 | 0.87 | CYP1A2 (0.46) | CYP1A2CLK4CYP2C9ATRCYP3A4 | |
| SCHEMBL16332497 | 0.87 | CYP1A2 (0.45) | CYP1A2CLK4CYP2C9CYP3A4FYN | |
| SCHEMBL16332582 | 0.86 | PIK3CA (0.48) | CYP1A2CLK4CYP2C9FYNSRC | |
| SCHEMBL16332056 | 0.85 | FYN (0.47) | CYP1A2CLK4CYP2C9CYP3A4FYN | |
| SCHEMBL16331852 | 0.85 | PDE4B (0.47) | CYP1A2CLK4CYP2C9ATRCYP3A4 | |
| SCHEMBL16332942 | 0.84 | CYP1A2 (0.43) | CYP1A2CLK4CYP2C9CYP3A4FYN | |
| SCHEMBL16331953 | 0.82 | TTK (0.50) | CYP1A2CLK4CYP2C9CYP3A4FYN | |
| SCHEMBL16331911 | 0.82 | FYN (0.55) | CYP1A2CYP2C9CYP3A4FYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| WO-2014207260-A1 | PYRROLO[3,2-C]PYRIDINE COMPOUNDS AS G-PROTEIN-COUPLED RECEPTOR KINASE 5 (GRK5) MODULATORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | WO | disclosed |
| EP-2818472-A1 | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | CYP1A2 4066/4885CLK4 118/4885CYP2C9 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.